OSI Forum: Buprenorphine in France From Zero to 75,000 patients in Five Years Location: OSI-Baltimore Event Date(s): November 19, 2003 Event Time: 4:00 p.m. - 6:00 p.m. Guest Speaker(s): Dr. Marc Auriacombe, Dr. William Lowenstein, Dr. Mario Sanchez
Buprenorphine is a highly effective treatment for heroin addiction which was recently approved for use in the United States. It is the first opioid that can be prescribed by physicians in the U.S. since the passage of the Harrison Narcotic Act in 1914. French physicians have more than five years experience treating patients with this medication. The widespread use of buprenorphine in France has led to a dramatic nation-wide reduction in heroin overdose deaths and in other harms associated with addiction. Our speakers, three French physicians who conduct research and oversee clinical services, will report on their experiences with this treatment. A discussion following the presentation will highlight differences between U.S. and French drug policy and provide an update on buprenorphine in Baltimore
Presented by The Open Society Institute–Baltimore Drug Addiction Treatment Program and The Johns Hopkins School of Public Health.
400 West 59th Street | New York, NY 10019, U.S.A. | Tel 1-212-548-0600
OSI-New York and OSI-Budapest are separate organizations that operate independently yet cooperate informally with each other. This website, a joint presentation, is intended to promote both organizations’ interests while maintaining their respective transparency.